XML 38 R24.htm IDEA: XBRL DOCUMENT
v3.19.2

Supplementary Quarterly Financial Data (Unaudited) | 12 Months Ended
--- | ---
Jun. 30, 2019
Quarterly Financial Data [Abstract] |
Supplementary Quarterly Financial Data (Unaudited) |
1 7. | SUPPLEMENTARY QUARTERLY FINANCIAL DATA (UNAUDITED)
Unaudited financial data by quarter for fiscal 2019.
In millions, except per share amounts |  | Quarters Ended |
|  | Jun 30, |  |  | Mar 31, |  |  | Dec 31, |  |  | Sep 30, |
Consolidated Statement of Operations Data: |  | 2019 |  |  | 2019 |  |  | 2018 |  |  | 2018 |
Molecular diagnostic testing |  | $ | 196.9 |  |  | $ | 200.5 |  |  | $ | 203.0 |  |  | $ | 189.0 |
Pharmaceutical and clinical services |  |  | 18.5 |  |  |  | 16.1 |  |  |  | 13.8 |  |  |  | 13.3 |
Total Revenue |  |  | 215.4 |  |  |  | 216.6 |  |  |  | 216.8 |  |  |  | 202.3 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of molecular diagnostic testing |  |  | 41.6 |  |  |  | 40.3 |  |  |  | 44.0 |  |  |  | 42.3 |
Cost of pharmaceutical and clinical services |  |  | 9.0 |  |  |  | 8.3 |  |  |  | 8.1 |  |  |  | 7.4 |
Research and development expense |  |  | 20.9 |  |  |  | 21.5 |  |  |  | 22.4 |  |  |  | 21.1 |
Change in the fair value of contingent consideration |  |  | (0.3 | ) |  |  | — |  |  |  | 1.0 |  |  |  | 0.4 |
Selling, general and administrative expense |  |  | 149.8 |  |  |  | 140.6 |  |  |  | 135.2 |  |  |  | 129.9 |
Total costs and expenses |  |  | 221.0 |  |  |  | 210.7 |  |  |  | 210.7 |  |  |  | 201.1 |
Operating income |  |  | (5.6 | ) |  |  | 5.9 |  |  |  | 6.1 |  |  |  | 1.2 |
Other income (expense): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest income |  |  | 0.9 |  |  |  | 0.7 |  |  |  | 0.9 |  |  |  | 0.7 |
Interest expense |  |  | (3.2 | ) |  |  | (3.2 | ) |  |  | (3.4 | ) |  |  | (2.2 | )
Other |  |  | 0.2 |  |  |  | (0.1 | ) |  |  | — |  |  |  | 1.1 |
Total other income (expense) |  |  | (2.1 | ) |  |  | (2.6 | ) |  |  | (2.5 | ) |  |  | (0.4 | )
Income before income taxes |  |  | (7.7 | ) |  |  | 3.3 |  |  |  | 3.6 |  |  |  | 0.8 |
Income tax provision |  |  | (3.4 | ) |  |  | (3.6 | ) |  |  | 1.0 |  |  |  | 1.6 |
Net income |  |  | (4.3 | ) |  |  | 6.9 |  |  |  | 2.6 |  |  |  | (0.8 | )
Net loss attributable to non-controlling interest |  |  | (0.1 | ) |  |  | — |  |  |  | — |  |  |  | (0.1 | )
Net income attributable to Myriad Genetics, Inc. stockholders |  | $ | (4.2 | ) |  | $ | 6.9 |  |  | $ | 2.6 |  |  | $ | (0.7 | )
Earnings per share: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | (0.06 | ) |  | $ | 0.09 |  |  | $ | 0.04 |  |  | $ | (0.01 | )
Diluted |  | $ | (0.06 | ) |  | $ | 0.09 |  |  | $ | 0.03 |  |  | $ | (0.01 | )
Weighted average shares outstanding: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  |  | 73.4 |  |  |  | 73.3 |  |  |  | 74.2 |  |  |  | 73.0 |
Diluted |  |  | 74.8 |  |  |  | 74.9 |  |  |  | 76.5 |  |  |  | 73.0 |
In millions, except per share amounts |  | Quarters Ended |
|  | Jun 30, |  |  | Mar 31, |  |  | Dec 31, |  |  | Sep 30, |
Consolidated Statement of Operations Data: |  | 2018 (a) |  |  | 2018 (a) |  |  | 2017 (a) |  |  | 2017 (a) |
Molecular diagnostic testing |  | $ | 180.6 |  |  | $ | 169.3 |  |  | $ | 173.1 |  |  | $ | 167.4 |
Pharmaceutical and clinical services |  |  | 13.3 |  |  |  | 13.8 |  |  |  | 14.8 |  |  |  | 11.4 |
Total Revenue |  |  | 193.9 |  |  |  | 183.1 |  |  |  | 187.9 |  |  |  | 178.8 |
Costs and expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of molecular diagnostic testing |  |  | 38.0 |  |  |  | 36.8 |  |  |  | 37.7 |  |  |  | 36.2 |
Cost of pharmaceutical and clinical services |  |  | 7.7 |  |  |  | 7.3 |  |  |  | 6.7 |  |  |  | 6.8 |
Research and development expense |  |  | 17.7 |  |  |  | 18.5 |  |  |  | 16.8 |  |  |  | 17.8 |
Change in contingent consideration |  |  | 0.2 |  |  |  | (1.2 | ) |  |  | 13.0 |  |  |  | (73.2 | )
Selling, general and administrative expense |  |  | 112.5 |  |  |  | 107.9 |  |  |  | 107.4 |  |  |  | 107.2 |
Total costs and expenses |  |  | 176.1 |  |  |  | 169.3 |  |  |  | 181.6 |  |  |  | 94.8 |
Operating income |  |  | 17.8 |  |  |  | 13.8 |  |  |  | 6.3 |  |  |  | 84.0 |
Other income (expense): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest income |  |  | 0.5 |  |  |  | 0.5 |  |  |  | 0.4 |  |  |  | 0.4 |
Interest Expense |  |  | (1.1 | ) |  |  | (0.5 | ) |  |  | (0.7 | ) |  |  | (0.9 | )
Other |  |  | 0.8 |  |  |  | (0.5 | ) |  |  | (0.4 | ) |  |  | (0.3 | )
Total other income (expense) |  |  | 0.2 |  |  |  | (0.5 | ) |  |  | (0.7 | ) |  |  | (0.8 | )
Income before income taxes |  |  | 18.0 |  |  |  | 13.3 |  |  |  | 5.6 |  |  |  | 83.2 |
Income tax provision |  |  | 3.5 |  |  |  | 4.3 |  |  |  | (25.3 | ) |  |  | 4.5 |
Net income |  |  | 14.5 |  |  |  | 9.0 |  |  |  | 30.9 |  |  |  | 78.7 |
Net loss attributable to non-controlling interest |  |  | — |  |  |  | (0.1 | ) |  |  | — |  |  |  | (0.1 | )
Net income attributable to Myriad Genetics, Inc. stockholders |  | $ | 14.5 |  |  | $ | 9.1 |  |  | $ | 30.9 |  |  | $ | 78.8 |
Earnings per share: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | 0.21 |  |  | $ | 0.13 |  |  | $ | 0.45 |  |  | $ | 1.15 |
Diluted |  | $ | 0.20 |  |  | $ | 0.13 |  |  | $ | 0.43 |  |  | $ | 1.12 |
Weighted average shares outstanding: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  |  | 70.1 |  |  |  | 69.8 |  |  |  | 69.3 |  |  |  | 68.6 |
Diluted |  |  | 72.9 |  |  |  | 72.4 |  |  |  | 71.9 |  |  |  | 70.4 |
(a) | Amounts adjusted due to the adoption of Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606). See Note 1 to the financial statements of this report for additional information.

X
- References No definition available. + Details
Name: | us-gaap_QuarterlyFinancialDataAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -URI http://asc.fasb.org/topic&trid=2126967 + Details
Name: | us-gaap_QuarterlyFinancialInformationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration